NEUROCRINE BIOSCIENCES INC Investment Income, Nonoperating
NEUROCRINE BIOSCIENCES INC (NBIX) reported Investment Income, Nonoperating of $102.00 thousand for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-10-31.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNonoperating · last filed 2011-10-31
- NEUROCRINE BIOSCIENCES INC investment income, nonoperating for the quarter ending 2011-09-30 was $102.00K, a 13.56% decline year-over-year.
- NEUROCRINE BIOSCIENCES INC investment income, nonoperating for the quarter ending 2011-06-30 was $120.00K.
- NEUROCRINE BIOSCIENCES INC investment income, nonoperating for the quarter ending 2010-09-30 was $118.00K.
- NEUROCRINE BIOSCIENCES INC investment income, nonoperating for the quarter ending 2010-06-30 was -$65.00K.
| Period end | Investment Income, Nonoperating 3 month | Investment Income, Nonoperating 6 month | Investment Income, Nonoperating 9 month |
|---|---|---|---|
| 2011-09-30 | $102.00K 10-Q · filed 2011-10-31 | $222.00K derived: sum of 2 quarters · filed 2011-10-31 | $341.00K 10-Q · filed 2011-10-31 |
| 2011-06-30 | $120.00K 10-Q · filed 2011-07-29 | $239.00K 10-Q · filed 2011-07-29 | |
| 2010-09-30 | $118.00K 10-Q · filed 2011-10-31 | $53.00K derived: sum of 2 quarters · filed 2011-10-31 | $732.00K 10-Q · filed 2011-10-31 |
| 2010-06-30 | -$65.00K 10-Q · filed 2011-07-29 | $614.00K 10-Q · filed 2011-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |